Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 5 versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 5 versus TRIOSTAT.
THYROLAR-0.5 vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone replacement; L-thyroxine (T4) is converted to active triiodothyronine (T3) which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate and oxygen consumption.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Initial dose 0.5 tablets (30 mg T4/7.5 mg T3) orally once daily, titrated every 2-4 weeks based on TSH, free T4, and free T3 levels; usual maintenance 0.5-2 tablets (30-120 mg T4/7.5-30 mg T3) once daily.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
For liothyronine (T3): approximately 1.5-2.5 days; for levothyroxine (T4): approximately 6-7 days. In hyperthyroidism, half-life may be shortened; in hypothyroidism, prolonged.
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal (approximately 40-50% as unchanged drug and conjugates), fecal (approximately 20-30% via biliary elimination), with the remainder metabolized and eliminated via urine and feces.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone